BREAKTHROUGH STUDY REVEALS VARENICLINE AND COUNSELING EFFECTIVE FOR DUAL USERS IN SMOKING CESSATION
The study found that the antismoking medication varenicline can increase rates of smoking abstinence without causing serious adverse events.
CoEHAR: NO HEALTH RESPIRATORY EFFECTS REPORTED WITH ECIG SUBSTITUTION FOR SMOKING
In their work “Respiratory health effects of e-cigarette substitution for tobacco cigarettes: a systematic review”, researchers analyzed 16 studies from 20 publications: most of the studies showed no difference in respiratory parameters. This indicates that electronic nicotine delivery systems substitution for smoking likely does not result in additional harm to respiratory health.
In Silico Science and Replica PI will attend the 6th THR summit, Athens
Two CoEHAR researchers will be part of this great event: The CoEHAR Director, Giovanni Li Volti, who is also PI of the replica project, will discuss the latest results of the Replica project and the IN silicon Science Pi, Dr. Renée O’Leary, will present her latest work.
REPLICA STUDY: CoEHAR research shows minimal to zero cancerogenic effects of e-cigarettes
Replica researchers performed a standard toxicology battery of three assays used for product assessment and regulatory applications.
DiaSmokeFree Working Group Challenges American Diabetes Association Guidelines on E-Cigarette Use
The DiaSmokeFree Working Group send a letter to the American Diabetes Association (ADA) expressing concern and seeking correction of a couple of statements in the ADA guidelines regarding the use…
CoEHAR letter to the European Commissioner for Health for a redefinition of anti-smoking policies
As requested by experts in the letter: "Our hope is that, in light of scientific evidence, the FCTC and the European Union conduct a careful, balanced, and transparent review of the available scientific evidence regarding non-combustible products, compared to conventional cigarettes, to provide indispensable information for making decisions in the interest of millions of smokers."
GTNF 2023: Polosa at the conference in Seoul, South Korea
“𝑊𝑒 𝑛𝑒𝑒𝑑 𝑡𝑜 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑒 𝑡𝑜𝑔𝑒𝑡ℎ𝑒𝑟 𝑠𝑜 𝑡ℎ𝑎𝑡 𝑒𝑣𝑒𝑟𝑦 𝑠𝑖𝑛𝑔𝑙𝑒 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑏𝑒𝑐𝑜𝑚𝑒𝑠 𝑎𝑛 𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑡𝑜𝑜𝑙. 𝑊𝑒 𝑑𝑜𝑛'𝑡 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑢𝑛𝑖𝑠ℎ 𝑎𝑢𝑡ℎ𝑜𝑟𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒𝑖𝑟 𝑗𝑢𝑛𝑘 𝑝𝑎𝑝𝑒𝑟𝑠, 𝑤𝑒 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑟𝑜𝑣𝑖𝑑𝑒 𝑡ℎ𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑡𝑜 𝑖𝑚𝑝𝑟𝑜𝑣𝑒”
6th Scientific Summit: latest findings by CoEHAR presented in Athens
The findings presented by CoEHAR researchers can contribute the discussions of ENDS for cessation and support harm reduction strategies in the world.
Bari, Polosa: “Risk reduction to fight atherosclerosis”
“However, it is important to understand a fact when talking about smoking: even today, nicotine is believed to play a major role in the developing of atherosclerosis” explains prof. Polosa “Nicotine does not cause atherosclerosis. In a survey conducted by SERMO on 1000 Italian doctors, it was found that 62 percent of the sample still think that atherosclerosis is caused by nicotine. The fact that 33 percent of the sample is made up of cardiologists is significant".
SRNT-E 2023: varenicline and vaping cessation at the London conference
On Monday 11 September, prof. Caponnetto has presented "Varenicline and counseling for vaping cessation: A double-blind, randomized, parallel-group, placebo-controlled trial".
- 1
- 2
- 3
- 4
- …
- 12
- Go to the next page
